about
Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicinp53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinomaThe role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinomaRecent advances in hepatocellular carcinoma therapy.New promising drug targets in cancer- and metastasis-initiating cells.Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.Notch1 binds and induces degradation of Snail in hepatocellular carcinoma.Mesothelin as a potential therapeutic target in human cholangiocarcinoma.Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues.SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice.Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutionsCannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome.Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancerAnti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone.Quinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathwayLncRNA CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR-384.Novel inhibitors in development for hepatocellular carcinoma.Immunobiology of hepatocellular carcinoma.Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model.Knockdown of HIF-1α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells.Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition.Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts.Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation.Licochalcone A induces apoptosis through endoplasmic reticulum stress via a phospholipase Cγ1-, Ca(2+)-, and reactive oxygen species-dependent pathway in HepG2 human hepatocellular carcinoma cells.Recombinant hHscFv-RC-RNase protein derived from transgenic tobacco acts as a bifunctional molecular complex against hepatocellular carcinoma.miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma.Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells.AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma.Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1α pre-mRNA in mice and in vitro.Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance.Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".New Tools for Molecular Therapy of Hepatocellular Carcinoma.Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma.Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinomaReactive oxygen species dependent phosphorylation of the liver kinase B1/AMP activated protein kinase/ acetyl-CoA carboxylase signaling is critically involved in apoptotic effect of lambertianic acid in hepatocellular carcinoma cells.
P2860
Q24292953-FAF1560F-240C-4151-81D2-2D23C485F316Q24306453-5F39C643-1A47-447A-82E0-3FAAC4BC19C5Q28477884-09BBA6C5-7EA5-4539-85B3-91D4A671ABECQ30236010-DD198E8E-BAA9-4A20-A694-2F731E7490E6Q34003691-5E8F79AB-24DE-4987-A648-7EE59C779BC9Q34062598-24BC78F9-AC87-4687-AEC4-3270FDB1B998Q34086677-DD3C8B40-AF0F-4B3C-95C7-D856D776744BQ34167021-E06F5505-03A6-4865-8600-13B9AA20AE47Q34884062-6AC0D0A3-C483-4620-8F2E-680D92D34C7AQ34999476-5219EC34-A372-4563-9436-2ECEFA40A8B4Q35495325-4417665F-4125-4833-8E69-574979F8101DQ35528377-6CD49738-4710-4DC0-BA55-3470D8F1DF16Q35545513-3FB1774A-C479-4E06-9400-1B31CE13B427Q35740123-7DB46650-453D-4426-9445-0173C3D168A6Q36372357-C06A853F-F6E4-4902-8E6E-2FACE1143F60Q36823677-14707CC0-F02E-4CFE-B8C8-93D62CB97D13Q36953182-6B47B94D-3EC6-4050-A44E-6EE27B42FE02Q37382536-E1D17D35-B5AC-45CB-AF80-9235E5B9DD5DQ37725994-7F29E080-794B-44EF-AA5F-A88EDD38D70DQ37863516-DF253262-4576-407F-A691-64BA2F56828AQ37914630-BE291523-6531-4C4C-930A-96A981A5F08DQ38783457-C8528321-360C-4A3D-8437-1542AA73C991Q38827855-BCE7CB42-AEEB-48A7-B2AC-95D75EDBB215Q38835387-00C39888-1773-447E-A2AE-63770F617B9DQ38972744-10048096-52A9-446B-B571-4B564586C3D9Q38978483-25B43549-05A9-4CAA-98FC-2AC5CA0370D3Q39043310-1070510A-EDCB-499D-A0DB-BD628D0AF4D6Q39166282-3BAB0FE5-C84A-459F-908E-D50462712E20Q39255366-40BB567B-791B-48BC-9E8C-34BFFAAD55FDQ39413543-906EED13-ACEF-4BE6-A0A3-0BE62F59A946Q39459058-2D193628-8163-43B2-BDD9-D1720C1D0295Q39561078-3568BEB0-5284-4E45-A998-8260FE00FD3CQ39622574-3AA57A3F-B77E-4543-B317-3D1832D0F9DCQ39687326-AECC8000-BAAD-4030-9B5D-38E6DF6911F4Q41544681-3683A3F3-2955-470D-9C74-26B4453214B2Q41889250-DD89CC22-22DB-4622-A5B8-B7B94D998C16Q42040454-8FDE2121-01FA-4CC7-8D16-A21256A6B69DQ42202989-54F0F38C-4AD3-4A7F-9034-7071ECD0FBB1Q42341423-44FE58BC-5DBA-4BF1-ACBD-A96F49176C66Q42378410-7D2EB22F-CD2B-45C3-9198-8ED3270724C0
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy for hepatocellular carcinoma.
@en
Targeted therapy for hepatocellular carcinoma.
@nl
type
label
Targeted therapy for hepatocellular carcinoma.
@en
Targeted therapy for hepatocellular carcinoma.
@nl
prefLabel
Targeted therapy for hepatocellular carcinoma.
@en
Targeted therapy for hepatocellular carcinoma.
@nl
P2093
P356
P1476
Targeted therapy for hepatocellular carcinoma.
@en
P2093
Hans Christian Spangenberg
Hubert E Blum
Robert Thimme
P2888
P304
P356
10.1038/NRGASTRO.2009.86
P407
P577
2009-06-02T00:00:00Z